Cold Agglutinin Disease

 

About Cold Agglutinin Disease

We are dedicated to transforming the lives of people with cold agglutinin disease.

Cold agglutinin disease is a rare, chronic autoimmune hemolytic anemia, which creates an unstable hemolytic state that negatively impacts health outcomes and quality of life.

Cold agglutinin disease is caused by an abnormal B-cell proliferation that results in IgM autoantibodies (cold agglutinins).

Cold agglutinins bind red blood cells (RBCs) and activate the classical complement pathway through the C1 complex.

Opsonin-coated RBCs travel to the liver and are phagocytosed, resulting in extravascular hemolysis.

Learn more about cold agglutinin disease and our commitment to addressing significant unmet needs that affect patients’ lives



Select Cold Agglutinin Disease Resources

Explore these pages to view select resources on the physiopathology of cold agglutinin disease, the potential impact on people living with cold agglutinin disease, and clinical management.

Cold agglutinin disease is caused by an abnormal B-cell proliferation that results in IgM autoantibodies (cold agglutinins).

Cold agglutinins bind red blood cells (RBCs) and activate the classical complement pathway through the C1 complex.

Opsonin-coated RBCs travel to the liver and are phagocytosed, resulting in extravascular hemolysis.

Click here to learn moreClick here to learn more

An overview of the complement cascade and its role in cold agglutinin disease was presented at Bioverativ’s Industry Update at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, December 2017 by Dr. Sandip Panicker, PhD, panel discussion member and Executive Director, Complement Research, Bioverativ, a Sanofi company, USA, and chaired by Dr. Sigbjørn Berentsen, MD, PhD, from the Department of Research and Innovation at Haugesund Hospital, Norway

View and download scientific presentation

Few natural history studies on cold agglutinin disease exist: Several small retrospective and longitudinal analyses have been published on the epidemiology, treatment, and burden of disease.

Click here to learn moreClick here to learn more

An overview of the natural history and burden of disease was presented at Bioverativ’s Industry Update at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, December 2017 by Dr. Catherine Broome, MD, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, USA and chaired by Dr. Sigbjørn Berentsen, MD, PhD, from the Department of Research and Innovation at Haugesund Hospital, Norway

Findings from these health care analyses demonstrate that people with cold agglutinin disease are chronically compromised and at an increased risk of thromboembolic events

View and download scientific presentation

There are no approved therapies for the treatment of cold agglutinin disease, a rare, chronic autoimmune hemolytic anemia.

Click here to learn moreClick here to learn more

An overview of the current treatment options was presented at Bioverativ’s Industry Update at the American Society of Hematology (ASH) annual meeting in Atlanta, GA, December 2017 by Dr. Ulrich Jäger, MD, Professor of Hematology, Head, Division of Hematology and Hemostaseology at the Medical University of Vienna, Austria and chaired by Dr. Sigbjørn Berentsen, MD, PhD, from the Department of Research and Innovation at Haugesund Hospital, Norway.

Clinical management options include nonpharmacological and pharmacological therapies, but treatment challenges and unmet needs still exist in addressing all aspects of cold agglutinin disease.

View and download scientific presentation



Select Cold Agglutinin Disease Scientific Publications

Here are a variety of select relevant publications from our researchers and others in the scientific community.

  1. Bass GF, et al. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014;13(4-5):560-564. Link to PubMed.
  2. Berentsen S, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460-466. Link to PubMed.
  3. Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126(22):2459-2465. Link to PubMed.
  4. Broome C, et al. Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort. ASH 2017; Poster 928. Please contact Medical Information to receive a copy: medinfo@Bioverativ.com or call 888-794-1415.
  5. Mullins M, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848. Link to PubMed.
  6. Swiecicki PL, et al. Cold agglutinin disease. Blood. 2013;122(7):1114-1121. Link to PubMed.
  7. Ungprasert P, et al. Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 2015;136(5):1013-1017. Link to PubMed.
  8. Yusuf HR, et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50-57. Link to PubMed.
  9. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547-1554. Link to PubMed.


Test Your Knowledge

Ready to test your skills? Gauge your knowledge about cold agglutinin disease today with our Myth or Fact Quiz!

Start the quiz Download the quiz

For medical or scientific information about our therapies:

Contact us at: medinfo@bioverativ.com or 888-794-1415